Floatz logo

STREPTOMYCIN

Tuberculosis, Pulmonary

FDA Office of Orphan Products DevelopmentSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Tuberculosis, Pulmonary cohort.

Asset / SponsorPhaseRating
IBUPROFEN
Fundació Institut Germans Trias i Pujol
Phase 2CCC
CRESTOMYCIN
FDA Office of Orphan Products Development
N/AD

Same molecule, other indications

STREPTOMYCIN is also rated in:

Mycobacterium avium complex diseaseDormant
B
Indicative ·
57 / 100
View asset →
Surgical Site InfectionDormant
D
Indicative ·
30 / 100
View asset →
colorectal cancerDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →